九洲药业(603456) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,751,242,194.31, representing a year-on-year increase of 27.49%[4] - Net profit attributable to shareholders for Q1 2023 was ¥280,694,039.23, up 35.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥274,128,312.35, reflecting a growth of 40.19% year-on-year[4] - Operating profit for Q1 2023 was ¥349,452,953.25, up from ¥253,540,462.07 in Q1 2022, reflecting a growth of 37.8%[20] - Net profit for Q1 2023 was ¥279,457,100.43, compared to ¥207,376,991.20 in Q1 2022, representing an increase of 34.8%[20] - Total comprehensive income amounted to CNY 280,874,570.57, an increase from CNY 206,478,271.34 in the previous period, reflecting a growth of approximately 36%[21] - Basic and diluted earnings per share increased to CNY 0.32 from CNY 0.25, representing a growth of 28%[21] Cash Flow and Liquidity - The net cash flow from operating activities amounted to ¥456,884,062.19, an increase of 19.49% from the previous year[4] - As of March 31, 2023, the company's cash and cash equivalents amounted to approximately RMB 4.03 billion, a significant increase from RMB 1.10 billion as of December 31, 2022, representing a growth of 268%[15] - Cash inflow from operating activities reached CNY 2,098,706,912.05, up from CNY 1,666,898,204.18, indicating a growth of about 25.8%[23] - Net cash flow from operating activities was CNY 456,884,062.19, compared to CNY 382,358,482.10 in the previous year, marking an increase of approximately 19.5%[23] - Cash inflow from financing activities totaled CNY 3,174,999,971.42, significantly higher than CNY 683,816,779.30 in the prior year, showing an increase of over 367%[24] - The net increase in cash and cash equivalents was CNY 3,017,760,716.20, compared to CNY 420,117,429.98 in the previous period, reflecting a substantial growth of approximately 618%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,954,903,596.51, a 38.44% increase from the end of the previous year[4] - Total assets as of Q1 2023 were ¥10,954,903,596.51, compared to ¥7,913,275,762.32 in Q1 2022, marking an increase of 38.8%[18] - Total liabilities for Q1 2023 were ¥2,820,331,852.67, up from ¥2,541,795,984.35 in Q1 2022, reflecting a growth of 10.9%[17] - The company’s long-term borrowings rose to ¥157,975,147.77 in Q1 2023, compared to ¥83,991,508.88 in Q1 2022, indicating an increase of 88.0%[17] Shareholder Information - Shareholders' equity attributable to the parent company reached ¥8,060,888,128.40, marking a 52.19% increase year-on-year[5] - The total equity attributable to shareholders reached ¥8,060,888,128.40 in Q1 2023, compared to ¥5,296,559,223.73 in Q1 2022, an increase of 52.5%[17] - The total number of ordinary shareholders at the end of the reporting period was 33,368[9] - The top ten shareholders include Zhejiang Zhongbei Jiuzhou Group Co., Ltd. with a 31.52% stake and Taizhou Gede Industrial Co., Ltd. with a 4.51% stake[11] Investment and Growth Strategies - The company is focused on expanding its CDMO business, which has significantly contributed to the revenue growth[5] - The company completed a non-public offering of A-shares in January 2023, raising approximately RMB 2.49 billion after deducting underwriting fees[13] - The company used RMB 600 million of the raised funds to increase investment in its projects and RMB 1.46 billion to supplement working capital[13] - The acquisition of 100% equity in the Zhongshan formulation factory from Sandos (China) was completed in March 2023, enhancing the company's CDMO capabilities[14] - The company continues to enhance its project-oriented management model to deepen relationships with major clients and expand its customer base[5] Inventory and Receivables - Accounts receivable increased to approximately RMB 825.46 million from RMB 671.11 million, reflecting a growth of 23% year-over-year[15] - Inventory decreased to approximately RMB 1.79 billion from RMB 2.02 billion, indicating a reduction of 12%[15] Research and Development - Research and development expenses for Q1 2023 amounted to ¥78,769,888.33, up from ¥64,192,677.61 in Q1 2022, indicating a growth of 22.7%[19] Financial Management - The company reported a decrease in financial expenses from ¥12,518,148.32 in Q1 2022 to ¥7,883,702.45 in Q1 2023, a reduction of 37.5%[19] - The company’s deferred tax assets increased from ¥23,999,576.14 in Q1 2022 to ¥33,774,264.48 in Q1 2023, a growth of 40.9%[16] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[25]